Voyager Therapeutics, Inc. (NASDAQ:VYGR) is on recovery track with 64.81% gain from a 1-year low price of $8.10. The company lost -7.29% to attain the price of $13.35 on 11/27/2017. Throughout the recent session, the prices were hovering between $13.27 and $14.6093. These shares are 107.49% off its target price of $27.7 and the current market capitalization stands at $354.18M. The recent change has given its price a -27.98% deficit over SMA 50 and -48.63% deficit over its 52-week high. The stock witnessed -38.02% declines, 45.11% gains and 51.02% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found VYGR’s volatility during a week at 8.32% and during a month it has been found around 9.74%.Voyager Therapeutics, Inc. (VYGR) Top Holders
Institutional investors currently hold around $163 million or 77% in VYGR stock. Look at its top three institutional owners. Fmr Llc owns $53.25 million in Voyager Therapeutics, Inc., which represents roughly 15.04% of the company’s market cap and approximately 32.67% of the institutional ownership. Similar statistics are true for the second largest owner, Adage Capital Partners Gp, L.L.C., which owns 975,000 shares of the stock are valued at $14.04 million. The third largest holder is Casdin Capital, Llc, which currently holds $11.74 million worth of this stock and that ownership represents nearly 3.31% of its market capitalization.Voyager Therapeutics, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 56 institutional holders increased their position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by some 2,465,134 shares, 18 decreased positions by 2,100,221 and 7 held positions by 6,748,127. That puts total institutional holdings at 11,313,482 shares, according to SEC filings. The stock grabbed 30 new institutional investments totaling 1,289,515 shares while 6 institutional investors sold out their entire positions totaling 1,430,779 shares.
Multiple company employees have indulged in significant insider trading. Voyager Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Medical Officer Ravina Bernard has sold 5,490 shares of Voyager Therapeutics, Inc. (VYGR) in trading session dated Nov. 10, 2017. These shares are worth $72,797 and were traded at $13.26 each. The SEC filing shows that Ravina Bernard performed a sale of 10,980 shares. The Chief Medical Officer disposed these shares by way of transaction on Oct. 10, 2017. The company’s shares were given away at $20.33 per share worth to an income of some $223,223 on account of Ravina Bernard.
Chief Medical Officer, Ravina Bernard, sold 16,470 common shares of Voyager Therapeutics, Inc. (VYGR) in the open market. In a transaction dated Sep. 11, 2017, the shares were put up for sale at an average price of $12.87, raking in a sum of $211,969. After this sale, 32,943 common shares of VYGR are directly owned by the insider, with total stake valued at $439,789.
In the transaction dated Sep. 05, 2017, the great number of shares disposed came courtesy the Chief Medical Officer; Ravina Bernard disposed a total of 5,490 shares at an average price of $10, amounting to approximately $54,900. The insider now directly owns 17,157 shares worth $229,046.Voyager Therapeutics, Inc. (VYGR) Analyst Guide
Several analysts have released their opinion on Voyager Therapeutics, Inc. (NASDAQ:VYGR), with 7 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.33 average brokerage recommendation.